Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs Among MSM
NCT05072093Phase 4Completed
- Sponsor
- Emory University
- Start
- Nov 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of emtricitabine + tenofovir disoproxil, doxycycline, cabotegravir in human immunodeficiency virus infection (HIV), sexually transmitted infection (STI), sponsored by Emory University. Started Nov 2021; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxildoxycyclinecabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)sexually transmitted infection (STI)
Beyond the preview
Go deeper on NCT05072093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072093.